Testing a drug to reduce ear damage from chemo in testicular cancer
Treatments studied
Part of Brain & nervous system, Cancer, Ear, nose & throat, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests whether adding Pedmark (sodium thiosulfate) to cisplatin chemotherapy can protect hearing in men with stage II or III testicular germ cell tumors. It aims to reduce the risk of drug-related ear damage while still treating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have testicular germ cell cancer (seminoma or non-seminoma) that has spread (stage II or III).
- You are scheduled to receive cisplatin chemotherapy for the first or second time, with a total planned dose of at least 300 mg per square meter of body surface.
- You have good kidney function, adequate blood cell counts, and normal liver function.
- You must be willing to have hearing tests before and during the study.
- You do not have severe hearing loss, unstable heart disease, or allergy to any component of Pedmark.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how radiotherapy, and possibly cisplatin chemotherapy, affect hearing in people treated for head and neck cancer. It may help doctors better predict hearing side effects and plan hearing monitoring or prevention.
This Phase 2 trial tests whether a cholesterol medicine called atorvastatin can protect hearing in people with head and neck cancer receiving cisplatin plus radiation. If it works, it may reduce the chance or severity of treatment-related hearing damage.
This study looks at how cisplatin chemotherapy affects hearing and balance in people with head and neck cancer. It compares patients who get cisplatin with those who only get radiation, to understand and possibly reduce these side effects.
This trial tests whether a medicine called sodium thiosulfate can protect your hearing from the side effects of cisplatin chemotherapy. It is for people with newly diagnosed cancer who are about to receive cisplatin for the first time.
This Phase 2 trial tests whether sodium thiosulfate and mannitol can reduce hearing damage (ototoxicity) in adults receiving cisplatin chemotherapy. It may help protect hearing while you get cancer treatment.
This Phase 3 study tests whether adding sodium thiosulfate during treatment for newly diagnosed medulloblastoma can reduce the risk of hearing loss. It is designed for children and teens whose cancer meets specific low-risk or average-risk tumor and lab features.
Hear when a new Hearing Loss trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.